NSE · AKSHARCHEM
AksharChem India Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹141 Cr with net profit ₹15 Cr — a 10.8% net margin, versus 4.58% the period before.
Shareholding
As of 2026-06-30
- Promoter62.7%
- Public37.25%
- DII0.06%
11,715 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.34× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Specialty Chemicals · ranked #12 of 18 by market cap · medians across 17 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Alkyl Amines Chemicals Ltd. | ₹9,552 Cr | 42.41 | 6.23 | 11.74% | 13.58% |
| Kingfa Science & Technology (India) Ltd. | ₹8,398 Cr | 37.21 | 6 | 13.24% | 10.16% |
| Apcotex Industries Limited | ₹3,117 Cr | 19.35 | 5.01 | 16.33% | 10.13% |
| DDev Plastiks Industries Ltd. | ₹2,657 Cr | 12.45 | 2.63 | 19.92% | 6.74% |
| Paushak Limited | ₹1,799 Cr | 42.44 | 3.66 | 8.01% | 17.21% |
| Premier Polyfilm Ltd. | ₹900 Cr | 25.72 | 6.11 | 21.66% | 9.59% |
| Sudarshan Colorants India Ltd. | ₹873 Cr | 16.89 | 1.52 | 7.81% | 6.03% |
| Kothari Petrochemicals Ltd. | ₹815 Cr | 11.3 | 2.19 | 19.47% | 12.46% |
| Chemcon Speciality Chemicals Ltd. | ₹796 Cr | 28.25 | 1.63 | 4.88% | 11.14% |
| Kronox Lab Sciences Ltd. | ₹653 Cr | 22.85 | 5.58 | 23.82% | 27.13% |
| AksharChem India Limited(this company) | ₹340 Cr | 27.51 | 1.28 | -0.82% | 3.38% |
AI analysis
AI-generated · google/gemini-2.5-flashAksharChem India Limited is listed with a market capitalization of Rs 188 Cr. The company reported revenue of Rs 346.52 Cr. The Price to Earnings (PE) ratio stands at 36.01, and the Earnings Per Share (EPS) is Rs 5.94. The company's book value is Rs 328.28.
Positives
- +Promoter holding is high at 62.6973% as of June 30, 2026.
- +Debt-to-equity ratio is relatively low at 0.23.
- +There are no pledged shares by promoters.
Negatives
- −Return on Equity (ROE) is low at 1.8%.
- −Return on Capital Employed (ROCE) is low at 0.183%.
- −The company reported negative net profits in September 2025 (Rs -1.37 Cr) and December 2025 (Rs -4.62 Cr).
- −Promoter shareholding has marginally decreased from 62.7024% in December 2018 to 62.6973% in June 2026.
- −The company is under ESM 1 surveillance.
Financial Performance
AksharChem India Limited reported a total revenue of Rs 346.52 Cr. The latest quarterly revenue for March 2026 was Rs 105.79 Cr, showing an increase compared to the previous quarter's revenue of Rs 80.38 Cr in December 2025. The net profit in March 2026 was Rs 4.84 Cr, a recovery from a net loss of Rs -4.62 Cr in December 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 1.8%, while the Return on Capital Employed (ROCE) is 0.183%. The Earnings Per Share (EPS) is Rs 5.94. Quarterly EPS improved to Rs 6.02 in March 2026, after a negative EPS of Rs -5.75 in December 2025.
Balance Sheet
AksharChem India Limited has a debt-to-equity ratio of 0.23, indicating a relatively low reliance on debt financing. The book value per share is Rs 328.28.
Ownership & Pledges
There are no pledged shares by the promoters. The number of shareholders is 11,715.
Regulatory & Surveillance
AksharChem India Limited is currently under ESM Stage 1 surveillance, which includes measures for Enhanced Surveillance Mechanism. This indicates a heightened monitoring by regulatory authorities.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.